Avance Biosciences Expands Testing Capabilities with CLIA Registration
Avance Biosciences has successfully achieved registration with the Clinical Laboratory Improvement Amendments (CLIA) program, marking a significant advancement in its capabilities for clinical trial support. This registration allows the company to conduct high-complexity laboratory testing, essential for clinical trials, regulatory submissions, and the development of companion diagnostics for biologic drugs.
Commitment to Quality and Reliability
Securing CLIA registration underscores Avance Biosciences' commitment to maintaining rigorous quality standards and meeting federal regulatory requirements. The infrastructure and quality systems established by the company ensure reliable and reproducible critical clinical trial data, which is paramount for advancing biopharmaceutical developments.
Comprehensive Testing Services
Through its registration with CLIA, Avance Biosciences offers a diverse range of services including biomarker validation, pharmacogenomics, immunogenicity testing, and specialized assays tailored to support clinical trials and diagnostic development. This comprehensive suite of services positions the company as a preferred partner in the evolving landscape of drug development.
Industry Recognition and Future Plans
Xuening Huang, the CEO of Avance Biosciences, expressed the importance of this milestone by stating, "CLIA registration represents a significant step forward for Avance Biosciences as we continue to expand our support for clinical trials and biopharmaceutical development." The company's facility has been recognized by industry experts for its preparedness, reinforcing Avance's dedication to providing high-quality, regulatory-compliant testing solutions.
Supporting Diverse Drug Development
The CLIA registration enables Avance Biosciences to assist clients in the development pipeline of various small molecule drugs and biologics, including mRNA therapeutics, vaccines, monoclonal antibodies, antibody-drug conjugates, and cell therapeutics. With compliance to CLIA standards, the company ensures the accuracy and consistency of clinical data necessary for regulatory approvals.
About Avance Biosciences
Avance Biosciences is a leading provider of GLP/GMP-compliant analytical services aimed at supporting the development of biological drugs and companion diagnostics. The company specializes in genomic, proteomic, immunoassay, and cell-based assay solutions tailored to meet the specific needs of biopharmaceutical innovators.
Frequently Asked Questions
What is CLIA registration?
CLIA registration allows laboratories to perform tests that meet specific quality standards set by the Clinical Laboratory Improvement Amendments.
How does Avance Biosciences support clinical trials?
Avance Biosciences provides a variety of testing services including biomarker validation and pharmacogenomics to support clinical trial data reliability.
Who is the CEO of Avance Biosciences?
Xuening Huang is the CEO of Avance Biosciences, focusing on expanding the company's clinical trial support.
What types of drugs does Avance work with?
Avance works with small molecule drugs, biologics, mRNA therapeutics, and many other innovative therapies.
How does Avance ensure testing quality?
The company implements rigorous quality systems and infrastructure required to meet CLIA and federal regulatory standards, ensuring data accuracy.
